Analyzing skin cells and immune response in systemic sclerosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the heterogeneity of fibroblasts and immune cells in the skin of patients with systemic sclerosis (SSc). By analyzing blood samples and skin biopsies, the study seeks to understand the interactions between B lymphocytes and fibroblasts, which are crucial in the disease's pathophysiology. The research focuses on the molecular signatures of these cells to provide insights into the varying severity of SSc. This could lead to a better understanding of the disease and potential future therapeutic targets.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Man or woman over 18 years of age
* With a systemic sclerosis meeting the ACR-EULAR 2013 criteria Having signed an informed consent
* Being insured

Exclusion Criteria:

* Syndrome of overlap with another connective tissue disease according to the international diagnostic criteria
* Immunosuppressive treatment within 12 months
* Dosage of current corticosteroid therapy ≥10mg/d
* Protected minors or adults
* Pregnant or breastfeeding women
* Deprived of their liberty
* Persons in emergency situations
* Persons who have refused or are unable to give informed consent

Where it's running

• Hop Claude Huriez Chu Lille
  Lille, France Recruiting

Study contacts

• Principal investigator: David Launay, MD,PhD — University Hospital, Lille
• Study coordinator: David Launay, MD,PhD
• Email: david.launay@chru-lille.fr
• Phone: 0320445962

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Test of HBM7020 in healthy adults and adults with autoimmune diseases

  This first-in-human study tests whether HBM7020 is safe and how it acts in the body for people with autoimmune diseases like RA, SLE, Sjögren's, and SSc compared with healthy volunteers.

  Recruiting Phase 1 Otsuka Pharmaceutical Development & Commercialization, Inc. · Brisbane, Queensland · NCT07649265

• Anti-CD19/BCMA universal CAR-T cell therapy for refractory autoimmune diseases

  This will try anti-CD19/BCMA universal CAR-T cell therapy in adults with refractory rheumatoid arthritis, dermatomyositis, systemic lupus, or systemic sclerosis to see if it is safe and can control their disease.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07558850

• Immun4Cure Cohort of Autoimmune Diseases

  A long-term, 500-person database and biobank is being built to study autoimmune diseases like RA, SLE, and scleroderma, plus healthy adults, using deep profiling and regular follow-ups over five years.

  Recruiting University Hospital, Montpellier · Montpellier · NCT07515638

• Nerandomilast for Systemic Sclerosis in Adults

  This study tests whether nerandomilast tablets can help adults with systemic sclerosis compared to a placebo.

  Recruiting at 67 sites Phase 3 Boehringer Ingelheim · Birmingham, Alabama and 247 other locations · NCT07497087

• AZD0120 CD19/BCMA CAR T-cell therapy for systemic sclerosis, inflammatory myopathies, and difficult-to-treat rheumatoid arthritis

  This trial will try a dual-targeting CD19/BCMA CAR T-cell treatment (AZD0120) in adults with systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis to see if it is safe and well tolerated.

  Recruiting at 5 sites Phase 1/2 AstraZeneca · Tucson, Arizona and 26 other locations · NCT07295847

• Phase 1 safety test of XmAb657 in healthy adults and people with myositis, scleroderma, or Sjögren's

  This study will test whether subcutaneous injections of XmAb657 are safe and well tolerated in healthy adults and people with autoimmune diseases such as idiopathic inflammatory myopathies, systemic sclerosis, or primary Sjögren's syndrome.

  Recruiting Phase 1 Xencor, Inc. · Melbourne · NCT07284797

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.